FDA Approves First Treatment for Severe Frostbite

Indonesia Berita Berita

FDA Approves First Treatment for Severe Frostbite
Indonesia Berita Terbaru,Indonesia Berita utama
  • 📰 MedicineNet
  • ⏱ Reading Time:
  • 33 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 51%

The U.S. Food and Drug Administration (FDA) on Wednesday approved the first treatment for severe frostbite.

Known as Aurlumyn , the injected medication lowers the risk of finger or toe amputation in cases of profound“This approval provides patients with the first-ever treatment option for severe frostbite,” Dr. Norman Stockbridge, director of the Division of Cardiology and Nephrology in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

Frostbite can range from mild cases that don't require medical intervention and don't cause permanent skin damage to severe cases where both the skin and underlying tissue are frozen and blood flow is stopped. In those instances, amputation is sometimes required, the FDA said. The FDA approval hinged on the results of a trial that randomized 47 adults with severe frostbite, all of whom receivedGroup 1 received iloprost intravenously for six hours a day for up to eight days.

None of the 16 patients receiving iloprost alone was found to need amputation, compared to 19% of patients in Group 2 and 60% of patients in Group 3.

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

MedicineNet /  🏆 575. in US

Indonesia Berita Terbaru, Indonesia Berita utama

Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.

Andy Kim sinks first lady Tammy Murphy in NJ Senate race’s first Democratic conventionAndy Kim sinks first lady Tammy Murphy in NJ Senate race’s first Democratic conventionHis victory shows he can get support of the rank-and-file Democrats he'll need to overcome Tammy Murphy's advantages.
Baca lebih lajut »

Hot 100 First-Timers: BossMan Dlow Scores His First Chart Hit With ‘Get In With Me’Hot 100 First-Timers: BossMan Dlow Scores His First Chart Hit With ‘Get In With Me’BossMan Dlow debuts on the Hot 100 with 'Get In With Me.' Get the details.
Baca lebih lajut »

The Morning After: Samsung gets FDA approval for its sleep apnea feature on Galaxy WatchThe Morning After: Samsung gets FDA approval for its sleep apnea feature on Galaxy WatchMat Smith heads up Engadget’s daily newsletter from London, UK. He has worked at Engadget for over a decade and has covered console gaming, flagship smartphones, the Apple Watch and fitness tech that promises to make him faster or stronger. He’s currently learning how to backflip.
Baca lebih lajut »

FDA-Approved Genetic Tests for Targeted Therapies and Risk AssessmentFDA-Approved Genetic Tests for Targeted Therapies and Risk AssessmentLearn about the FDA-approved genetic tests that can identify patients with specific genetic mutations, assess their risk for certain health conditions, and guide treatment decisions.
Baca lebih lajut »

Experts Warn Against Unregulated Dietary Supplements and Protein PowdersExperts Warn Against Unregulated Dietary Supplements and Protein PowdersLearn why dietary supplement labels can be misleading and why the FDA is cracking down.
Baca lebih lajut »

FDA Denies Application for New Antifungal DrugFDA Denies Application for New Antifungal DrugThe Food and Drug Administration has denied an application for a new antifungal drug called olorofim, requesting more data. Fungal infections pose a growing threat to human health, and doctors are in need of new medicines to combat this problem.
Baca lebih lajut »



Render Time: 2025-02-25 10:21:40